GS 9857

Drug Profile

GS 9857

Alternative Names: GS-9857

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 01 Apr 2016 Gilead Sciences completes a phase II trial in Hepatitis C (Combination therapy) in USA, Puerto Rico and New Zealand (PO) (NCT02378935)
  • 01 Mar 2016 Gilead Sciences completes a phase I pharmacokinetics trial in volunteers with normal hepatic function and patients with hepatic impairment in USA, Germany and New Zealand (NCT02397707)
  • 01 May 2015 Phase-I clinical trials in Hepatitis C (Monotherapy) in Germany, USA, New Zealand (PO) (NCT02402452 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top